Diabetic Foot Care — Cost, Top Hospitals & Success Rates | MyMedicPlus

Diabetic foot care is a specialised area of diabetes management addressing the unique vulnerability of the feet in people with diabetes due to the combined effects of peripheral neuropathy (nerve damage reducing protective sensation), peripheral artery disease (PAD) causing reduced blood supply, and impaired immune response leading to increased infection susceptibility. These three pathological pathways create a 'perfect storm' for foot complications — minor injuries go unnoticed (due to neuropathy), heal slowly (due to ischaemia and immune impairment), and escalate rapidly into serious infections that can threaten the limb and the patient's life.

Diabetic foot complications are the leading cause of non-traumatic lower limb amputation globally. The International Working Group on the Diabetic Foot (IWGDF) estimates that every 30 seconds a lower limb is lost due to diabetes somewhere in the world. Diabetic foot ulcers (DFU) affect approximately 15–25% of people with diabetes during their lifetime, and up to 20% of patients hospitalised for DFU require amputation. These statistics underscore the critical importance of prevention, early detection, and prompt multidisciplinary management.

Diabetic foot care operates on two levels: preventive foot care (education, regular professional foot examination, appropriate footwear, and nail care) for all diabetic patients, and active wound management for patients who develop foot ulcers. The multidisciplinary diabetic foot team includes diabetologists, podiatrists, vascular surgeons, orthotists, infectious disease specialists, and wound care nurses — working together to implement the four pillars of DFU management: offloading, wound debridement and dressing, infection control, and vascular assessment and revascularisation.

Diabetic foot care addresses the full spectrum of lower extremity complications in diabetes. Peripheral neuropathy — present in 50% of people with diabetes of 25 years' duration — is characterised by loss of protective sensation (inability to feel pain, temperature, or pressure), motor neuropathy causing foot deformity (claw toes, Charcot foot), and autonomic neuropathy causing dry, cracked skin from anhidrosis. These neuropathic changes are managed through regular foot inspection, moisturising, and custom footwear.

Diabetic foot ulcers are classified using the Wagner classification (grades 0–5) or the SINBAD score (Site, Ischaemia, Neuropathy, Bacterial infection, Area, Depth) to guide management. Neuropathic ulcers (typically plantar, over pressure points, well-perfused, punched-out appearance) are managed primarily with offloading (total contact cast, removable cast walker). Ischaemic ulcers (typically digital, on the dorsum or margins, with poor perfusion) require vascular intervention before healing can occur. Neuroischaemic ulcers combine both pathologies and are the highest-risk category. Charcot neuroarthropathy — acute bone and joint destruction due to neuropathy — presents as acute unilateral foot swelling and warmth, and requires urgent offloading to prevent progressive deformity. Infected DFU (cellulitis, deep space infection, osteomyelitis) requires urgent antibiotic therapy and surgical debridement.

All people with diabetes should receive basic preventive foot care education and annual professional foot examination. The IWGDF risk stratification classifies patients by ulcer risk: Risk 0 (no neuropathy, no PAD — annual examination); Risk 1 (neuropathy or PAD — 6-monthly examination); Risk 2 (neuropathy + PAD, or foot deformity — 3–6 monthly examination); Risk 3 (previous ulcer or amputation — 1–3 monthly examination by diabetic foot specialist). Higher-risk patients benefit from referral to a specialised diabetic foot clinic and custom orthopaedic footwear.

Patients requiring active DFU treatment should be assessed and managed by a multidisciplinary team. Vascular assessment (ankle-brachial index, toe pressures, or TcPO2 — transcutaneous oxygen pressure) is mandatory for all DFUs to determine whether ischaemia is a contributing factor requiring revascularisation. Surgical debridement is indicated for necrotic tissue, sloughy wounds, or deep space infection. Osteomyelitis (bone infection underlying an ulcer) requires either prolonged antibiotic therapy (6 weeks or more) or surgical debridement/resection, determined by the extent of bone involvement on MRI. Amputation — minor (toe, ray, transmetatarsal) or major (below-knee, above-knee) — is reserved for limb-threatening infection unresponsive to limb-salvage efforts or non-reconstructible ischaemia.

Offloading is the most important treatment for plantar neuropathic DFUs — removing pressure from the ulcer to allow healing. Total contact casting (TCC) is the gold standard, achieving healing in 65–90% of appropriately selected neuropathic ulcers within 6–8 weeks. Removable cast walkers (RCWs) are effective when worn consistently but have lower compliance; rendering them irremovable significantly improves outcomes. Surgical offloading through Achilles tendon lengthening or flexor tendon transfer addresses underlying biomechanical causes of plantar pressure and significantly reduces DFU recurrence rates.

Wound debridement — removal of necrotic, infected, or devitalised tissue — is performed by sharp debridement (scalpel/curette) at each wound care visit to maintain a healthy wound bed. Negative pressure wound therapy (NPWT/VAC therapy) accelerates granulation tissue formation in complex wounds. Bioengineered skin substitutes (Dermagraft, Apligraf) and growth factors (PDGF — becaplermin/Regranex) provide additional benefit for non-healing wounds unresponsive to standard care. Infection management with targeted antibiotics based on wound culture sensitivity is essential — empirical broad-spectrum antibiotics are used initially for severe infections while awaiting culture results. Vascular intervention — percutaneous transluminal angioplasty (PTA) or surgical bypass — restores blood flow to the ischaemic foot and is a prerequisite for healing of ischaemic DFUs. Multidisciplinary diabetic foot clinics — combining podiatry, vascular surgery, orthotics, infectious disease, and endocrinology — deliver superior outcomes to single-specialty management for complex diabetic foot pathology.

Structured preventive diabetic foot care programmes produce dramatic reductions in DFU incidence and amputation rates. The International Consensus on the Diabetic Foot and landmark studies from the Leicester Diabetic Foot Unit and Edinburg Royal Infirmary demonstrate that multidisciplinary diabetic foot care reduces major amputation rates by up to 85% compared to general diabetes care without specialist input. The economic impact is enormous — prevention of a single major amputation saves USD 50,000–100,000 in acute care costs plus ongoing rehabilitation expenses.

For established DFUs, total contact casting achieves healing in 65–90% of neuropathic ulcers within 12 weeks. Neuroischaemic ulcers treated with revascularisation achieve limb salvage in 70–80% of cases when performed promptly. Bioengineered tissue products increase healing rates by 30–40% compared to standard care alone in randomised trials. Patient education in foot self-care (daily foot inspection, appropriate nail care, moisturising, recognition of danger signs) is the single most cost-effective intervention in diabetic foot management, preventing the development of ulcers in high-risk patients.

Diabetic foot ulcers carry significant intrinsic morbidity: approximately 20% of hospitalised DFU patients require amputation, and the 5-year mortality following major amputation in diabetic patients exceeds 50% — comparable to many cancers. Infection — including deep space infection, necrotising fasciitis, and osteomyelitis — represents the greatest immediate risk. Osteomyelitis (infection of the underlying bone) occurs in approximately 20% of DFU cases and requires either prolonged antibiotics or surgical bone debridement for resolution.

Charcot neuroarthropathy, if not recognised early and treated with urgent offloading, progresses to severe irreversible foot deformity (rocker-bottom foot, collapsed arch) that dramatically increases future ulceration risk. Peripheral artery disease — present in 40–50% of patients with DFU — significantly worsens ulcer healing and limb-threatening outcome. Critical limb ischaemia (rest pain, non-healing ulcers, or gangrene with ankle pressure below 50 mmHg) requires urgent vascular intervention for limb salvage. Recurrence of DFU after successful healing is extremely common (40–80% within 5 years) without sustained offloading, glycaemic control, and preventive footwear — emphasising that diabetic foot care is a lifelong programme, not an episode of acute treatment.

Following successful DFU healing, transition to a lifelong preventive programme is essential. High-risk patients require specialist podiatry review every 1–3 months with structured risk reassessment at each visit. Custom-made therapeutic footwear with appropriate insoles to redistribute plantar pressure is prescribed for all patients with a history of DFU — wearing standard footwear significantly increases recurrence risk. Patients must continue daily foot self-inspection, moisturising (avoiding interdigital spaces), and prompt reporting of any new lesion, discolouration, swelling, or wound.

Optimisation of all diabetes complications contributors — glycaemic control (HbA1c target below 7–8% depending on overall health), hypertension management, lipid management (statins for cardiovascular protection), and smoking cessation — form the medical backbone of long-term foot complication prevention. Recurrence risk is particularly high in the first 3 months after ulcer healing, warranting increased monitoring frequency during this period. Involvement of orthopaedic or vascular surgery in ongoing follow-up is maintained for patients with residual deformity, vascular insufficiency, or previous amputation.

Diabetic foot care costs span from affordable preventive measures to extremely expensive acute interventions. Basic preventive podiatry care in the United States costs USD 100–300 per visit; custom diabetic footwear USD 300–900 per pair (typically covered by Medicare for qualifying diabetic patients). Hospitalisation for infected DFU costs USD 10,000–50,000 per admission; below-knee amputation USD 30,000–70,000 plus rehabilitation. In the United Kingdom, NHS provides diabetic foot screening, podiatry, and DFU wound care as standard services. The total cost of diabetic foot disease to the NHS is estimated at over GBP 600 million annually.

Medical tourism for diabetic foot care primarily benefits patients seeking specialist podiatry review, wound care assessment, and vascular evaluation that may have long waiting lists at home. In India, specialist diabetic foot consultation costs USD 15–40; comprehensive wound care services at accredited diabetes centres cost USD 30–100 per session; vascular angioplasty for peripheral artery disease in diabetic patients costs USD 1,500–5,000 — 70–80% less than US costs. The Apollo Hospitals group, Fortis Healthcare, and multiple diabetes specialty centres in India offer comprehensive, internationally accredited diabetic foot care programmes. Emergency diabetic foot surgery (debridement, minor amputation) in high-cost countries can be delayed for stable patients who can safely travel to access equivalent quality care at lower cost in accredited overseas centres.

Hyperbaric oxygen therapy (HBOT) — exposure to 100% oxygen at supra-atmospheric pressure (typically 2–3 atmospheres) — increases tissue oxygen delivery in ischaemic wound environments and has clinical trial evidence supporting its use as an adjunct for Wagner grade 3–4 DFUs in patients who have had revascularisation but continue to have inadequate wound healing. Recommended as an adjunct in UHMS (Undersea and Hyperbaric Medical Society) guidelines for selected DFU cases.

Platelet-rich plasma (PRP) injection and growth factor preparations are used as adjuncts in some wound care protocols with emerging evidence for improved healing rates. Stem cell therapy injected into the ischaemic limb to promote angiogenesis (new blood vessel formation) is under investigation in clinical trials with promising early results for patients with critical limb ischaemia who are not candidates for conventional revascularisation. Biofilm-disrupting advanced wound dressings (DACC dressings, silver-based antimicrobials, iodine-cadexomer dressings) address the bacterial biofilm component of chronic DFUs that resists standard antibiotics. The prosthetic and rehabilitation pathway following major amputation — with well-fitted prostheses and physiotherapy — enables return to full mobility in selected patients and should be discussed early in the management of non-salvageable limbs.